The Journal of Immunology, Vol 146, Issue 9 2977-2982, Copyright © 1991 by American Association of Immunologists

ARTICLES

Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes

AJ Infante, PA Thompson, KA Krolick and KA Wall
Department of Pediatrics, University of Texas Health Science Center, San Antonio 78284-7810.

C57BL/6 (B6) mice respond to immunization with acetylcholine receptor (AChR) from Torpedo californica as measured by T cell proliferation, antibody production, and the development of muscle weakness resembling human myasthenia gravis. The congenic strain B6.C-H-2bm12 (bm12), which differs from B6 by three amino acid substitutions in the beta-chain of the MHC class II molecule I-A, develops a T cell proliferative response but does not produce antibody or develop muscle weakness. By examining the fine specificity of the B6 and bm12 T cell responses to AChR by using T cell clones and synthetic AChR peptides, we found key differences between the two strains in T cell epitope recognition. B6 T cells responded predominantly to the peptide representing alpha-subunit residues 146-162; this response was cross-reactive at the clonal level to peptide 111-126. Based on the sequence homology between these peptides and the T cell response to a set of truncated peptides, the major B6 T cell epitope was determined to be residues 148-152. The cross-reactivity of peptides 146-162 and 111-126 could also be demonstrated in vivo. Immunization of B6 mice with either peptide primed for T cell responses to both peptides. In contrast, immunization of bm12 mice with peptide 111-126 primed for an anti-peptide response, which did not cross-react with 146-162. Peptide-reactive T cells were not elicited after immunization of bm12 mice with 146-162. These results define a major T cell fine specificity in experimental autoimmune myasthenia gravis-susceptible B6 mice to be directed at alpha-subunit residues 148-152. T cells from disease-resistant bm12 mice fail to recognize this epitope but do recognize other portions of AChR. We postulate that alpha-148-152 is a disease-related epitope in murine experimental autoimmune myasthenia gravis. In this informative strain combination, MHC class II-associated determinant selection, rather than Ag responsiveness per se, may play a major role in determining disease susceptibility.

This article has been cited by other articles:

				W. Wang, M. Milani, N. Ostlie, D. Okita, R. K. Agarwal, R. Caspi, and B. M. Conti-Fine C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-{gamma} Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells J. Immunol., June 1, 2007; 178(11): 7072 - 7080. [Abstract] [Full Text] [PDF]

				H. Yang, M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis J. Immunol., February 1, 2005; 174(3): 1729 - 1737. [Abstract] [Full Text] [PDF]

				A. C. Vincent, J. McConville, J. Newsom-Davis, J. M. Lindstrom, and A. G. Engel Is "seronegative" MG explained by autoantibodies to MuSK? Neurology, January 25, 2005; 64(2): 399 - 399. [Full Text] [PDF]

				D. B. DRACHMAN, J-M. WU, A. MIAGKOV, M. A. WILLIAMS, R. N. ADAMS, and B. WU Specific Immunotherapy of Experimental Myasthenia by Genetically Engineered APCs: The "Guided Missile" Strategy Ann. N.Y. Acad. Sci., September 1, 2003; 998(1): 520 - 532. [Abstract] [Full Text] [PDF]

				N. Ostlie, M. Milani, W. Wang, D. Okita, and B. M. Conti-Fine Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57BL/6 Mice J. Immunol., January 1, 2003; 170(1): 604 - 612. [Abstract] [Full Text] [PDF]

				S. Stacy, B. E. Gelb, B. A. Koop, J. J. Windle, K. A. Wall, K. A. Krolick, A. J. Infante, and E. Kraig Split Tolerance in a Novel Transgenic Model of Autoimmune Myasthenia Gravis J. Immunol., December 1, 2002; 169(11): 6570 - 6579. [Abstract] [Full Text] [PDF]

				N. S. Ostlie, P. I. Karachunski, W. Wang, C. Monfardini, M. Kronenberg, and B. M. Conti-Fine Transgenic Expression of IL-10 in T Cells Facilitates Development of Experimental Myasthenia Gravis J. Immunol., April 15, 2001; 166(8): 4853 - 4862. [Abstract] [Full Text] [PDF]

				C. Deng, E. Goluszko, and P. Christadoss Fas/Fas Ligand Pathway, Apoptosis, and Clonal Anergy Involved in Systemic Acetylcholine Receptor T Cell Epitope Tolerance J. Immunol., March 1, 2001; 166(5): 3458 - 3467. [Abstract] [Full Text] [PDF]

				P. I. Karachunski, N. S. Ostlie, C. Monfardini, and B. M. Conti-Fine Absence of IFN-{gamma} or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice J. Immunol., May 15, 2000; 164(10): 5236 - 5244. [Abstract] [Full Text] [PDF]

				A. Saoudi, I. Bernard, A. Hoedemaekers, B. Cautain, K. Martinez, P. Druet, M. De Baets, and J.-C. Guery Experimental Autoimmune Myasthenia Gravis May Occur in the Context of a Polarized Th1- or Th2-Type Immune Response in Rats J. Immunol., June 15, 1999; 162(12): 7189 - 7197. [Abstract] [Full Text] [PDF]

				D. B. DRACHMAN, K. R. McINTOSH, and B. YANG Factors That Determine the Severity of Experimental Myasthenia Gravisa Ann. N.Y. Acad. Sci., May 13, 1998; 841(1): 262 - 282. [Full Text]

				R. Raju, W.-Z. Zhan, P. Karachunski, B. Conti-Fine, G. C. Sieck, and C. David Polymorphism at the HLA-DQ Locus Determines Susceptibility to Experimental Autoimmune Myasthenia Gravis J. Immunol., May 1, 1998; 160(9): 4169 - 4174. [Abstract] [Full Text] [PDF]